[go: up one dir, main page]

MA52400A1 - Combined vaccine composition for multiple administration - Google Patents

Combined vaccine composition for multiple administration

Info

Publication number
MA52400A1
MA52400A1 MA52400A MA52400A MA52400A1 MA 52400 A1 MA52400 A1 MA 52400A1 MA 52400 A MA52400 A MA 52400A MA 52400 A MA52400 A MA 52400A MA 52400 A1 MA52400 A1 MA 52400A1
Authority
MA
Morocco
Prior art keywords
vaccine
composition
combination
present
combination vaccine
Prior art date
Application number
MA52400A
Other languages
French (fr)
Other versions
MA52400B1 (en
Inventor
Suk Young Choi
Yoon Ae Noh
Eun Ji Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA52400A1 publication Critical patent/MA52400A1/en
Publication of MA52400B1 publication Critical patent/MA52400B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A61K31/115—Formaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition immunogène à doses multiples pour un vaccin combiné multivalent, dans laquelle (i) le vaccin combiné multivalent contient un vaccin contre la coqueluche vaccin à cellules entières (wp) ou un vaccin contre la coqueluche acellulaire(ap), et un vaccin contre la polio inactivé sabin (sipv) ; et (ii) la composition contient du 2-phénoxyéthanol (2-pe) et du formaldéhyde (hcho) en tant que conservateurs ; et un procédé de préparation d’une composition immunogène à doses multiples pour un vaccin combiné multivalent. Il a été confirmé que la combinaison de 2-phénoxyéthanol et de formaldéhyde selon la présente invention est un excellent conservateur capable de maintenir une capacité antimicrobienne et qu’elle peut être efficacement utilisée pour produire une composition à doses multiples, maintenir la capacité antimicrobienne d’un vaccin combiné, ce de sorte que la composition de la présente invention puisse être efficacement utilisée dans l’industrie des vaccins combinés à doses multiples.The present invention relates to a multiple dose immunogenic composition for a multivalent combination vaccine, wherein (i) the multivalent combination vaccine contains a whole cell vaccine (wp) pertussis vaccine or an acellular pertussis (ap) vaccine, and sabin inactivated polio vaccine (ipsv); and (ii) the composition contains 2-phenoxyethanol (2-pe) and formaldehyde (hcho) as preservatives; and a method of preparing a multidose immunogenic composition for a multivalent combination vaccine. It has been confirmed that the combination of 2-phenoxyethanol and formaldehyde according to the present invention is an excellent preservative capable of maintaining antimicrobial capacity and can be effectively used to produce a multi-dose composition, maintain antimicrobial capacity of a combination vaccine, so that the composition of the present invention can be effectively used in the multiple dose combination vaccine industry.

MA52400A 2015-09-16 2016-09-13 Combined vaccine composition for multiple administration MA52400B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150131157 2015-09-16
PCT/KR2016/010313 WO2017048038A1 (en) 2015-09-16 2016-09-13 Combination vaccine composition for multiple-dosage

Publications (2)

Publication Number Publication Date
MA52400A1 true MA52400A1 (en) 2022-06-30
MA52400B1 MA52400B1 (en) 2023-01-31

Family

ID=58289554

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42317A MA42317B2 (en) 2015-09-16 2016-09-13 Combination vaccine composition for multiple administration
MA52400A MA52400B1 (en) 2015-09-16 2016-09-13 Combined vaccine composition for multiple administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA42317A MA42317B2 (en) 2015-09-16 2016-09-13 Combination vaccine composition for multiple administration

Country Status (7)

Country Link
KR (1) KR101864029B1 (en)
BR (1) BR112018005291A2 (en)
EA (1) EA037283B1 (en)
MA (2) MA42317B2 (en)
PH (1) PH12018500570A1 (en)
TN (1) TN2018000063A1 (en)
WO (1) WO2017048038A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102101879B1 (en) * 2017-03-15 2020-05-29 주식회사 엘지화학 Multivalent vaccine composition against streptococcus
SG11202000224SA (en) * 2017-07-18 2020-02-27 Serum Inst Of India Pvt Ltd An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (en) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920009729B1 (en) * 1990-08-29 1992-10-22 주식회사 녹십자 Mixed vaccine of d.p.t. and hepatitis b
KR920009729A (en) * 1990-11-26 1992-06-25 전금자 Pottery manufacturing method that generates far infrared rays
ATE444079T1 (en) * 1992-05-23 2009-10-15 Glaxosmithkline Biolog Sa COMBINED VACCINES CONTAINING HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS
ES2582635T3 (en) * 2007-09-12 2016-09-14 Galderma Research & Development Use of excipients as preservatives and pharmaceutical compositions containing them
PE20100365A1 (en) * 2008-10-24 2010-05-21 Panacea Biotec Ltd NEW COMBINATION VACCINES WITH WHOLE CELL COUGH AND METHOD FOR THEIR PREPARATION
TR201811280T4 (en) * 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Mixed vaccines with low antigen and / or adjuvant doses.

Also Published As

Publication number Publication date
BR112018005291A2 (en) 2018-10-09
WO2017048038A1 (en) 2017-03-23
KR20170033254A (en) 2017-03-24
MA52400B1 (en) 2023-01-31
PH12018500570A1 (en) 2018-09-17
TN2018000063A1 (en) 2019-07-08
MA42317B2 (en) 2021-11-30
KR101864029B1 (en) 2018-06-01
EA037283B1 (en) 2021-03-04
EA201890502A1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
MA52400B1 (en) Combined vaccine composition for multiple administration
MX2023009011A (en) Cdk inhibitor.
CY1121418T1 (en) HEPATITIS VIRUS INHIBITORS C
GT201500021A (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
MX2019005379A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof.
MX2017002028A (en) Pyrrolopyrimidine compounds used as tlr7 agonist.
CL2017002230A1 (en) Combined treatment with a tlr7 agonist and inhibitor of vhb capsid assembly.
AR101674A1 (en) USE OF A TRICYCLIC COMPOUND CONTAINING NITROGEN
MX2018002728A (en) VACCINE COMPOSITIONS THAT HAVE IMPROVED STABILITY AND IMMUNOGENICITY.
BR112016008468A2 (en) FORMULA COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND, USE OF A COMPOUND, AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF CANCER
MX388408B (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
BR112015008417A2 (en) immunogenic composition and vaccine
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
MX384875B (en) METHOD FOR OBTAINING A MYCOPLASMA VACCINE.
IN2013MU00711A (en)
MX381617B (en) PEPTIDE-CURCUMIN CONJUGATES AND FORMULATIONS THEREOF.
PE20211648A1 (en) COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT
AR112405A1 (en) TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES
MX2021012201A (en) WATER SOLUBLE ADJUVANT.
MX2016014740A (en) A METHOD FOR THE TREATMENT OF MOVEMENT DISORDERS WITH BEFIRADOL.
EA201391512A1 (en) SOLID PHARMACEUTICAL COMPOSITION